ProfileGDS5678 / 1460366_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 72% 70% 76% 73% 72% 73% 77% 74% 73% 75% 74% 73% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8518174
GSM967853U87-EV human glioblastoma xenograft - Control 24.5839272
GSM967854U87-EV human glioblastoma xenograft - Control 34.3834470
GSM967855U87-EV human glioblastoma xenograft - Control 45.2253176
GSM967856U87-EV human glioblastoma xenograft - Control 54.6650973
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5676972
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6977373
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2331177
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8214674
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.702973
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9329375
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8269674
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6445873
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5711672